Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial

DOI Web Site Web Site 被引用文献1件

収録刊行物

  • The Lancet

    The Lancet 402 (10415), 1835-1847, 2023-11

    Elsevier BV

被引用文献 (1)*注記

もっと見る

問題の指摘

ページトップへ